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While most factors used as reprogramming transgenes can be replaced by other means, Oct4 has remained
essential until now. Three recent papers have now broken this barrier through the use of opposing lineage
specifying transgenes and chemical modulation, thus signifying a milestone in advancing our understanding
of pluripotency induction.Seven years ago, Takahashi and Yama-
naka (2006) provided a method to repro-
gram somatic cells to induced pluripotent
stem cells (iPSCs) by using a small group
of transcription factors, OCT4, SOX2,
KLF4, and c-MYC, that are highly ex-
pressed in mouse and human embryonic
stem cells (ESCs). Other core pluripo-
tency genes such as NANOG and LIN28
that are also enriched in ESCs and iPSCs
were later added to achieve reprogram-
ming of human fibroblasts or enhance
reprogramming efficiency of refractory
somatic cell types. A prevailing model
that effectively explains the existing data
is the following: once overexpressed in
somatic cells, these core pluripotency
genes switch on the core transcriptional
circuitry associated with pluripotency,
change or reverse expression of genes
controlling the somatic cell fate, and grad-
ually establish a pluripotent state that is
maintained by endogenous core genes.
This model also predicts and explains
the success of using other transgenes
(including microRNAs) or small molecules
to replace several of these core pluripo-
tency factors as reprogramming trans-
genes. However, as a transgene, Oct4
has remained indispensable in somatic
cell reprogramming to iPSCs, underscor-
ing its master role in pluripotency regula-
tion. Moreover, recent investigation has
revealed that core pluripotency genes
(such as Oct4 and Sox2) also function in
lineage specification and their overex-
pression drives stem cells toward a spe-
cific embryonic germ layer (ectoderm,
mesoderm, or endoderm) while blocking
other lineages (Loh and Lim, 2011; Thom-
son et al., 2011; Wang et al., 2012). Based
on these insights, a new model has beenformulated that describes the pluripotent
state as a precarious balancing condition
that results from continuous competition
between rival lineage specifications (Loh
and Lim, 2011).
This new model, as opposed to the
classic ‘‘ground state’’ model of ESCs
and PSC induction by pluripotency fac-
tors, has now been substantiated by a
recent study in Cell (Shu et al., 2013). In
this elegant study, Shu et al. conducted a
large-scale search for genes that can
replaceOct4 as a transgene in the reprog-
ramming of mouse fibroblasts. Their
systematic analysis demonstrated that
Gata3, as well as other lineage-specifying
genes (such as Gata6) that are known to
positively regulate meso-endodermal
commitment, can replace Oct4 as a re-
programming factor. This substitution
ability likely operates by counteracting
the elevation of ectodermal genes
induced by Sox2 present the reprogram-
ming gene cocktail. Reciprocally, they
demonstrated that Gmnn, a known ecto-
dermal specifying factor, can replace
Sox2 in reprogramming, because it ham-
pers the elevation of meso-endodermal
genes induced by Oct4 present in the
reprogramming cocktail. Most strikingly,
they showed that concurrent coexpres-
sion of Gata3 and Gmnn can substitute
for Oct4 and Sox2 as transgenes for
reprogramming mouse fibroblasts to
iPSCs (in the presence of Klf4 and c-Myc
transgenes), thus eliminating the need
for any core pluripotency genes as
reprogramming factors. Their data sug-
gest a ‘‘seesaw’’ model wherein achieving
a precarious balance of the two
counteracting forces, commitment to
ectoderm and meso-endoderm lineages,Cell Stem Cell 13, Sresults in induction of pluripotency (Shu
et al., 2013).
Now, in this issue of Cell Stem
Cell, Montserrat et al. (2013) show that
lineage-specifying factors can also be
used to replaceOCT4 and SOX2 as trans-
genes in reprogramming human fibro-
blasts to iPSCs. Montserrat et al. (2013)
first observed that in addition to core
pluripotency markers (such as OCT4 and
SOX2), human PSCs express several
genes that were previously known for
roles in lineage specification. They found
that GATA3 plays a similarly powerful
role in lineage specification to that of
OCT4, and they successfully replaced
OCT4 with GATA3 in human fibroblast
reprogramming. Molecular analyses
revealed thatGATA3 andOCT4 can upre-
gulate eachother in thepresenceofSOX2,
KLF4, and c-MYC transgenes. Surpris-
ingly,GATA3 knockdown in human iPSCs
attenuated SOX2 and NANOG expres-
sion, but not OCT4, and resulted in iPSC
death, indicating that appropriate GATA3
expression is crucial for human iPSC or
ESC maintenance. Using similar logic,
the authors identified factors that are
related to ectoderm commitment and
demonstrated that ZNF521 can replace
SOX2. Lastly, they showed that GATA3
with a combination of three ectoderm
specifiers, ZNF521, OTX2, and PAX6,
can replace OCT4 and SOX2 for human
iPSC induction in the presence of KLF4
and c-MYC.
Taken together, data generated by
Montserrat et al. support the seesaw
model in which lineage-specifying factors
can replace OCT4 and SOX2 for
iPSC induction of human fibroblasts,
as previously proposed in the mouseeptember 5, 2013 ª2013 Elsevier Inc. 261
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et al., 2013).
It has been known for 20 years that
nullipotent embryonic germ cells could
be induced to pluripotency without any
pluripotency genes or any exogenous
genes (Matsui et al., 1992; Resnick et al.,
1992). As of recently, many pluripotency
factors, such as SOX2, have been suc-
cessfully replaced by small-molecule
compounds that alter cell signaling or
epigenetic landscapes of somatic cells
in reprogramming. However, the question
remained as to whether somatic cell re-
programming could be achieved with
minimal or even no exogenous genes,
mRNAs, or proteins. A recent study led
by Deng’s group now appears to have
an answer. Hou et al. (2013) have now
demonstrated that mouse fibroblasts
can be induced to iPSCs solely by
chemical manipulation, or more precisely,
by seven small molecule compounds. The
preliminary investigation of the under-
lying mechanisms of this process, called
chemical reprogramming, suggested
that the chemical combination activated
upstream genes of Oct4, like Sall4 and
Sox2, and also promoted Oct4 expres-
sion by epigenetic modulation. It remains
to be determined whether reprogramming
of human somatic cells to iPSCs can be
achieved solely by chemical means. It is
of importance to investigate whether
the chemical reprogramming of human
somatic cells by a cocktail of chemical262 Cell Stem Cell 13, September 5, 2013 ª2compounds (if feasible and efficient
enough) would be a better option than
that accomplished by either an RNA
cocktail or a nonintegrating method with
a single DNA vector that can be easily
manufactured under current good manu-
facture practices (cGMP) conditions.
Time will tell which method is preferred
by most practitioners for generation of
cGMP-compliant iPSC lines, which is
also an economic, practical, and regula-
tory matter. The chemical reprogramming
approach, however, will no doubt provide
new insights into the minimal or alternate
requirements for pluripotency induction.
In the exciting journey toward reducing
genes and developing better methods for
somatic cell reprogramming, these recent
studies have shown that the Oct4 trans-
gene can be replaced finally by the line-
age-specifying genes or a cocktail of
small molecules. Therefore, none of the
original four Yamanaka factors, in addi-
tion to Nanog, Lin28, and many other
pluripotency genes, are indispensable.
This recent unexpected development in
the journey to understand and solve the
pluripotency mystery reminds us of
the nursery rhyme that mirrors the plot in
the detective novel ‘‘And Then There
Were None’’ authored by Agatha Christie.
These findings do not mean that core plu-
ripotency genes such as Oct4 and Sox2
are not important. These recent advances
signify that we are now entering a new
phase of reprogramming technology that013 Elsevier Inc.focuses on the means to better decipher
the molecular mechanisms and networks
of pluripotency induction, and more
broadly of cell fate determination in a
nonlinear fashion. It seems fitting to
describe this milestone with whatWinston
Churchill once said: ‘‘Now this is not
the end. It is not even the beginning of
the end. But it is, perhaps, the end of the
beginning.’’REFERENCES
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